Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
Journal of Clinical Oncology · 20.11.2023 · 41 (33) · 5080-5089
DOI: 10.1200/jco.22.02773 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2023. Verfasst von A de Gramont und 17 weiteren Autor:innen. Beteiligte Einrichtung: From the Service de Médecine Interne-OncologieHôpital Saint-Antoine, Paris; Debiopharm, Charenton; Service d'Oncologie Médicale, Centre Hospitalier L…. Die Arbeit wurde bisher 31-mal zitiert (Crossref).
Abstract (Originalsprache)
PURPOSE In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen. This phase III study investigated the effect of combining oxaliplatin with LV5FU2, with progression-free survival as the primary end point. PATIENTS AND METHODS Four hundred twenty previously untreated patients with measurable disease were randomized to receive a 2-hour infusion of LV (200 mg/m 2 /d) followed by a 5FU bolus (400 mg/m 2 /d) and 22-hour infusion (600 mg/m 2 /d) for 2 consecutive days every 2 weeks, either alone or together with oxaliplatin 85 mg/m 2 as a 2-hour infusion on day 1. RESULTS Patients allocated to oxaliplatin plus LV5FU2 had significantly longer progression-free survival (median, 9.0 v 6.2 months; P = .0003) and better response rate (50.7% v 22.3%; P = .0001) when compared with the control arm. The improvement in overall survival did not reach significance (median, 16.2 v 14.7 months; P = .12). LV5FU2 plus oxaliplatin gave higher frequencies of National Cancer Institute common toxicity criteria grade 3/4 neutropenia (41.7% v 5.3% of patients), grade 3/4 diarrhea (11.9% v 5.3%), and grade 3 neurosensory toxicity (18.2% v 0%), but this did not result in impairment of quality of life (QoL). Survival without disease progression or deterioration in global health status was longer in patients allocated to oxaliplatin treatment ( P = .004). CONCLUSION The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
Autor:innen und Institutionen
- From the Service de Médecine Interne-OncologieHôpital Saint-Antoine, Paris; Debiopharm, Charenton; Service d'Oncologie Médicale, Centre Hospitalier Lyon Sud, Pierre-Benite; and Centre Hospitalier René Dubos, Pontoise, F…
Zitieren
APA
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., Papamichael, D., Le Bail, N., Louvet, C., Hendler, D., de Braud, F., Wilson, C., Morvan, F., & Bonetti, A. (2023). Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. Journal of Clinical Oncology, 41(33), 5080-5089. https://doi.org/10.1200/jco.22.02773
Vancouver
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. Journal of Clinical Oncology. 2023;41(33):5080-5089. doi:10.1200/jco.22.02773
BibTeX
@article{deGramont2023,
author = {de Gramont, A and Figer, A and Seymour, M and Homerin, M and Hmissi, A and Cassidy, J and Boni, C and Cortes-Funes, H and Cervantes, A and Freyer, G and Papamichael, D and Le Bail, N and Louvet, C and Hendler, D and de Braud, F and Wilson, C and Morvan, F and Bonetti, A},
title = {Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {33},
pages = {5080--5089},
doi = {10.1200/jco.22.02773}
}
EUVIMED